NasdaqCM · Biotechnology

Whitehawk Therapeutics (WHWK)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+58.6%

$7.50 average target

$4.73-0.10 (-2.1%)Latest market snapshot · Yahoo Finance

Market cap$269.7M

Cash$190.0M

Quarterly burn$14.5M

Pipeline assets3

Short float12.5%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 58.6% upsideTargets are estimates—not guarantees—and can change after company updates.

$7.50Average target

Wall Street consensus

BuyCalculated from 8 current ratings

8ratings

Buy 5Hold 3Sell 0

Price-target range

$7.50

+58.6%

Low $4.00High $10.00

CurrentAverage

Bear case$4.00-15.4%

Base case$7.50+58.6%

Bull case$10.00+111.4%

Analyst coverage6published opinions

Bullish share63%buy recommendations

Target spread$6low-to-high dispersion

Consensus score—1.0 is strongest

Recommendation mix

Current rating breakdown

8 tracked ratings

Company profile

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.